A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism
A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. The calcimimetic agent R-568 lowers plasma parathyroid hormone (PTH) levels in hemodialysis patients with mild secondary hyperparathyroidism, but its efficacy in those with more severe secon...
Gespeichert in:
| Veröffentlicht in: | Kidney international 2000-07, Vol.58 (1), p.436-445 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 445 |
|---|---|
| container_issue | 1 |
| container_start_page | 436 |
| container_title | Kidney international |
| container_volume | 58 |
| creator | Goodman, William G. Frazao, Joao M. Goodkin, David A. Turner, Stewart A. Liu, Wei Coburn, Jack W. |
| description | A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism.
The calcimimetic agent R-568 lowers plasma parathyroid hormone (PTH) levels in hemodialysis patients with mild secondary hyperparathyroidism, but its efficacy in those with more severe secondary hyperparathyroidism has not been studied.
Twenty-one patients undergoing hemodialysis three times per week with plasma PTH levels between 300 and 1200 pg/mL were randomly assigned to 15 days of treatment with either 100 mg of R-568 (N = 16) or placebo (N = 5). Plasma PTH and blood ionized calcium levels were measured at intervals of up to 24 hours after oral doses on days 1, 2, 3, 5, 8, 11, 12, and 15.
Pretreatment PTH levels were 599 ± 105 (mean ± SE) and 600 ± 90 pg/mL in subjects given R-568 or placebo, respectively, and values on the first day of treatment did not change in those given placebo. In contrast, PTH levels fell by 66 ± 5%, 78 ± 3%, and 70 ± 3% at one, two, and four hours, respectively, after initial doses of R-568, remaining below pretreatment values for 24 hours. Blood ionized calcium levels also decreased after the first dose of R-568 but did not change in patients given placebo. Despite lower ionized calcium concentrations on both the second and third days of treatment, predose PTH levels were 422 ± 70 and 443 ± 105 pg/mL, respectively, in patients given R-568, and values fell each day by more than 50% two hours after drug administration. Predose PTH levels declined progressively over the first nine days of treatment with R-568 and remained below pretreatment levels for the duration of study. Serum total and blood ionized calcium concentrations decreased from pretreatment levels in patients given R-568, whereas values were unchanged in those given placebo. Blood ionized calcium levels fell below 1.0 mmol/L in 7 of 16 patients receiving R-568; five patients withdrew from study after developing symptoms of hypocalcemia, whereas three completed treatment after the dose of R-568 was reduced.
The calcimimetic R-568 rapidly and markedly lowers plasma PTH levels in patients with secondary hyperparathyroidism caused by end-stage renal disease. |
| doi_str_mv | 10.1046/j.1523-1755.2000.00183.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_210128746</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0085253815471169</els_id><sourcerecordid>980867351</sourcerecordid><originalsourceid>FETCH-LOGICAL-c505t-f69af596faa8cb5f3ba04e0b94bc93ff940ade3a28cc4064fd3f5cd98653e9393</originalsourceid><addsrcrecordid>eNqFkE1v1DAQhi1URJfCX6gs1GvCOLZT-1iq8iFV4gJny3HGrFdJnNrZdvff42VXbW-c5jDPOx8PIZRBzUC0nzc1kw2v2LWUdQMANQBTvN69IavnxhlZAShZNZKrc_I-500BlebwjpwzUKqVulmR4YY6O7gwhhGX4Kj9g9NCh_iEKdN5sHm0dLbJLut9iqGn65jGOCEd8BGHTMNUuksomUyfwrKmGV2cepv2dL2fMb2Khjx-IG-9HTJ-PNUL8vvr3a_b79X9z28_bm_uKydBLpVvtfVSt95a5TrpeWdBIHRadE5z77UA2yO3jXJOQCt8z710vS4vcdRc8wvy6Th3TvFhi3kxm7hNU1lpGgasUdeiLZA6Qi7FnBN6M6cwlssNA3OwbDbmINMcZJqDZfPPstmV6OVp_rYbsX8VPGotwNUJsLno9clOLuQXTjRaSFWwL0esqMTHgMlkV1w67ENCt5g-hv8f8xcMc54l</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>210128746</pqid></control><display><type>article</type><title>A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Goodman, William G. ; Frazao, Joao M. ; Goodkin, David A. ; Turner, Stewart A. ; Liu, Wei ; Coburn, Jack W.</creator><creatorcontrib>Goodman, William G. ; Frazao, Joao M. ; Goodkin, David A. ; Turner, Stewart A. ; Liu, Wei ; Coburn, Jack W.</creatorcontrib><description>A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism.
The calcimimetic agent R-568 lowers plasma parathyroid hormone (PTH) levels in hemodialysis patients with mild secondary hyperparathyroidism, but its efficacy in those with more severe secondary hyperparathyroidism has not been studied.
Twenty-one patients undergoing hemodialysis three times per week with plasma PTH levels between 300 and 1200 pg/mL were randomly assigned to 15 days of treatment with either 100 mg of R-568 (N = 16) or placebo (N = 5). Plasma PTH and blood ionized calcium levels were measured at intervals of up to 24 hours after oral doses on days 1, 2, 3, 5, 8, 11, 12, and 15.
Pretreatment PTH levels were 599 ± 105 (mean ± SE) and 600 ± 90 pg/mL in subjects given R-568 or placebo, respectively, and values on the first day of treatment did not change in those given placebo. In contrast, PTH levels fell by 66 ± 5%, 78 ± 3%, and 70 ± 3% at one, two, and four hours, respectively, after initial doses of R-568, remaining below pretreatment values for 24 hours. Blood ionized calcium levels also decreased after the first dose of R-568 but did not change in patients given placebo. Despite lower ionized calcium concentrations on both the second and third days of treatment, predose PTH levels were 422 ± 70 and 443 ± 105 pg/mL, respectively, in patients given R-568, and values fell each day by more than 50% two hours after drug administration. Predose PTH levels declined progressively over the first nine days of treatment with R-568 and remained below pretreatment levels for the duration of study. Serum total and blood ionized calcium concentrations decreased from pretreatment levels in patients given R-568, whereas values were unchanged in those given placebo. Blood ionized calcium levels fell below 1.0 mmol/L in 7 of 16 patients receiving R-568; five patients withdrew from study after developing symptoms of hypocalcemia, whereas three completed treatment after the dose of R-568 was reduced.
The calcimimetic R-568 rapidly and markedly lowers plasma PTH levels in patients with secondary hyperparathyroidism caused by end-stage renal disease.</description><identifier>ISSN: 0085-2538</identifier><identifier>EISSN: 1523-1755</identifier><identifier>DOI: 10.1046/j.1523-1755.2000.00183.x</identifier><identifier>PMID: 10886592</identifier><identifier>CODEN: KDYIA5</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adult ; Aniline Compounds - administration & dosage ; Aniline Compounds - adverse effects ; Area Under Curve ; Biological and medical sciences ; Calcium - agonists ; Calcium - blood ; chronic renal disease ; Double-Blind Method ; end-stage renal disease ; Endocrinopathies ; Female ; hemodialysis ; Humans ; Hyperparathyroidism, Secondary - blood ; Hyperparathyroidism, Secondary - drug therapy ; Hyperparathyroidism, Secondary - etiology ; Hypocalcemia - chemically induced ; Kidney Failure, Chronic - complications ; Male ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; Nephropathies. Renovascular diseases. Renal failure ; Non tumoral diseases. Target tissue resistance. Benign neoplasms ; parathyroid hormone ; Parathyroid Hormone - blood ; Parathyroids. Parafollicular cells. Cholecalciferol. Phosphocalcic homeostasis (diseases) ; Phenethylamines ; Propylamines ; R-568 ; Renal failure</subject><ispartof>Kidney international, 2000-07, Vol.58 (1), p.436-445</ispartof><rights>2000 International Society of Nephrology</rights><rights>2000 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Jul 2000</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c505t-f69af596faa8cb5f3ba04e0b94bc93ff940ade3a28cc4064fd3f5cd98653e9393</citedby><cites>FETCH-LOGICAL-c505t-f69af596faa8cb5f3ba04e0b94bc93ff940ade3a28cc4064fd3f5cd98653e9393</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1429458$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10886592$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Goodman, William G.</creatorcontrib><creatorcontrib>Frazao, Joao M.</creatorcontrib><creatorcontrib>Goodkin, David A.</creatorcontrib><creatorcontrib>Turner, Stewart A.</creatorcontrib><creatorcontrib>Liu, Wei</creatorcontrib><creatorcontrib>Coburn, Jack W.</creatorcontrib><title>A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism</title><title>Kidney international</title><addtitle>Kidney Int</addtitle><description>A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism.
The calcimimetic agent R-568 lowers plasma parathyroid hormone (PTH) levels in hemodialysis patients with mild secondary hyperparathyroidism, but its efficacy in those with more severe secondary hyperparathyroidism has not been studied.
Twenty-one patients undergoing hemodialysis three times per week with plasma PTH levels between 300 and 1200 pg/mL were randomly assigned to 15 days of treatment with either 100 mg of R-568 (N = 16) or placebo (N = 5). Plasma PTH and blood ionized calcium levels were measured at intervals of up to 24 hours after oral doses on days 1, 2, 3, 5, 8, 11, 12, and 15.
Pretreatment PTH levels were 599 ± 105 (mean ± SE) and 600 ± 90 pg/mL in subjects given R-568 or placebo, respectively, and values on the first day of treatment did not change in those given placebo. In contrast, PTH levels fell by 66 ± 5%, 78 ± 3%, and 70 ± 3% at one, two, and four hours, respectively, after initial doses of R-568, remaining below pretreatment values for 24 hours. Blood ionized calcium levels also decreased after the first dose of R-568 but did not change in patients given placebo. Despite lower ionized calcium concentrations on both the second and third days of treatment, predose PTH levels were 422 ± 70 and 443 ± 105 pg/mL, respectively, in patients given R-568, and values fell each day by more than 50% two hours after drug administration. Predose PTH levels declined progressively over the first nine days of treatment with R-568 and remained below pretreatment levels for the duration of study. Serum total and blood ionized calcium concentrations decreased from pretreatment levels in patients given R-568, whereas values were unchanged in those given placebo. Blood ionized calcium levels fell below 1.0 mmol/L in 7 of 16 patients receiving R-568; five patients withdrew from study after developing symptoms of hypocalcemia, whereas three completed treatment after the dose of R-568 was reduced.
The calcimimetic R-568 rapidly and markedly lowers plasma PTH levels in patients with secondary hyperparathyroidism caused by end-stage renal disease.</description><subject>Adult</subject><subject>Aniline Compounds - administration & dosage</subject><subject>Aniline Compounds - adverse effects</subject><subject>Area Under Curve</subject><subject>Biological and medical sciences</subject><subject>Calcium - agonists</subject><subject>Calcium - blood</subject><subject>chronic renal disease</subject><subject>Double-Blind Method</subject><subject>end-stage renal disease</subject><subject>Endocrinopathies</subject><subject>Female</subject><subject>hemodialysis</subject><subject>Humans</subject><subject>Hyperparathyroidism, Secondary - blood</subject><subject>Hyperparathyroidism, Secondary - drug therapy</subject><subject>Hyperparathyroidism, Secondary - etiology</subject><subject>Hypocalcemia - chemically induced</subject><subject>Kidney Failure, Chronic - complications</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Nephropathies. Renovascular diseases. Renal failure</subject><subject>Non tumoral diseases. Target tissue resistance. Benign neoplasms</subject><subject>parathyroid hormone</subject><subject>Parathyroid Hormone - blood</subject><subject>Parathyroids. Parafollicular cells. Cholecalciferol. Phosphocalcic homeostasis (diseases)</subject><subject>Phenethylamines</subject><subject>Propylamines</subject><subject>R-568</subject><subject>Renal failure</subject><issn>0085-2538</issn><issn>1523-1755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkE1v1DAQhi1URJfCX6gs1GvCOLZT-1iq8iFV4gJny3HGrFdJnNrZdvff42VXbW-c5jDPOx8PIZRBzUC0nzc1kw2v2LWUdQMANQBTvN69IavnxhlZAShZNZKrc_I-500BlebwjpwzUKqVulmR4YY6O7gwhhGX4Kj9g9NCh_iEKdN5sHm0dLbJLut9iqGn65jGOCEd8BGHTMNUuksomUyfwrKmGV2cepv2dL2fMb2Khjx-IG-9HTJ-PNUL8vvr3a_b79X9z28_bm_uKydBLpVvtfVSt95a5TrpeWdBIHRadE5z77UA2yO3jXJOQCt8z710vS4vcdRc8wvy6Th3TvFhi3kxm7hNU1lpGgasUdeiLZA6Qi7FnBN6M6cwlssNA3OwbDbmINMcZJqDZfPPstmV6OVp_rYbsX8VPGotwNUJsLno9clOLuQXTjRaSFWwL0esqMTHgMlkV1w67ENCt5g-hv8f8xcMc54l</recordid><startdate>20000701</startdate><enddate>20000701</enddate><creator>Goodman, William G.</creator><creator>Frazao, Joao M.</creator><creator>Goodkin, David A.</creator><creator>Turner, Stewart A.</creator><creator>Liu, Wei</creator><creator>Coburn, Jack W.</creator><general>Elsevier Inc</general><general>Nature Publishing</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20000701</creationdate><title>A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism</title><author>Goodman, William G. ; Frazao, Joao M. ; Goodkin, David A. ; Turner, Stewart A. ; Liu, Wei ; Coburn, Jack W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c505t-f69af596faa8cb5f3ba04e0b94bc93ff940ade3a28cc4064fd3f5cd98653e9393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adult</topic><topic>Aniline Compounds - administration & dosage</topic><topic>Aniline Compounds - adverse effects</topic><topic>Area Under Curve</topic><topic>Biological and medical sciences</topic><topic>Calcium - agonists</topic><topic>Calcium - blood</topic><topic>chronic renal disease</topic><topic>Double-Blind Method</topic><topic>end-stage renal disease</topic><topic>Endocrinopathies</topic><topic>Female</topic><topic>hemodialysis</topic><topic>Humans</topic><topic>Hyperparathyroidism, Secondary - blood</topic><topic>Hyperparathyroidism, Secondary - drug therapy</topic><topic>Hyperparathyroidism, Secondary - etiology</topic><topic>Hypocalcemia - chemically induced</topic><topic>Kidney Failure, Chronic - complications</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Nephropathies. Renovascular diseases. Renal failure</topic><topic>Non tumoral diseases. Target tissue resistance. Benign neoplasms</topic><topic>parathyroid hormone</topic><topic>Parathyroid Hormone - blood</topic><topic>Parathyroids. Parafollicular cells. Cholecalciferol. Phosphocalcic homeostasis (diseases)</topic><topic>Phenethylamines</topic><topic>Propylamines</topic><topic>R-568</topic><topic>Renal failure</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goodman, William G.</creatorcontrib><creatorcontrib>Frazao, Joao M.</creatorcontrib><creatorcontrib>Goodkin, David A.</creatorcontrib><creatorcontrib>Turner, Stewart A.</creatorcontrib><creatorcontrib>Liu, Wei</creatorcontrib><creatorcontrib>Coburn, Jack W.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Kidney international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goodman, William G.</au><au>Frazao, Joao M.</au><au>Goodkin, David A.</au><au>Turner, Stewart A.</au><au>Liu, Wei</au><au>Coburn, Jack W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism</atitle><jtitle>Kidney international</jtitle><addtitle>Kidney Int</addtitle><date>2000-07-01</date><risdate>2000</risdate><volume>58</volume><issue>1</issue><spage>436</spage><epage>445</epage><pages>436-445</pages><issn>0085-2538</issn><eissn>1523-1755</eissn><coden>KDYIA5</coden><abstract>A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism.
The calcimimetic agent R-568 lowers plasma parathyroid hormone (PTH) levels in hemodialysis patients with mild secondary hyperparathyroidism, but its efficacy in those with more severe secondary hyperparathyroidism has not been studied.
Twenty-one patients undergoing hemodialysis three times per week with plasma PTH levels between 300 and 1200 pg/mL were randomly assigned to 15 days of treatment with either 100 mg of R-568 (N = 16) or placebo (N = 5). Plasma PTH and blood ionized calcium levels were measured at intervals of up to 24 hours after oral doses on days 1, 2, 3, 5, 8, 11, 12, and 15.
Pretreatment PTH levels were 599 ± 105 (mean ± SE) and 600 ± 90 pg/mL in subjects given R-568 or placebo, respectively, and values on the first day of treatment did not change in those given placebo. In contrast, PTH levels fell by 66 ± 5%, 78 ± 3%, and 70 ± 3% at one, two, and four hours, respectively, after initial doses of R-568, remaining below pretreatment values for 24 hours. Blood ionized calcium levels also decreased after the first dose of R-568 but did not change in patients given placebo. Despite lower ionized calcium concentrations on both the second and third days of treatment, predose PTH levels were 422 ± 70 and 443 ± 105 pg/mL, respectively, in patients given R-568, and values fell each day by more than 50% two hours after drug administration. Predose PTH levels declined progressively over the first nine days of treatment with R-568 and remained below pretreatment levels for the duration of study. Serum total and blood ionized calcium concentrations decreased from pretreatment levels in patients given R-568, whereas values were unchanged in those given placebo. Blood ionized calcium levels fell below 1.0 mmol/L in 7 of 16 patients receiving R-568; five patients withdrew from study after developing symptoms of hypocalcemia, whereas three completed treatment after the dose of R-568 was reduced.
The calcimimetic R-568 rapidly and markedly lowers plasma PTH levels in patients with secondary hyperparathyroidism caused by end-stage renal disease.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>10886592</pmid><doi>10.1046/j.1523-1755.2000.00183.x</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0085-2538 |
| ispartof | Kidney international, 2000-07, Vol.58 (1), p.436-445 |
| issn | 0085-2538 1523-1755 |
| language | eng |
| recordid | cdi_proquest_journals_210128746 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult Aniline Compounds - administration & dosage Aniline Compounds - adverse effects Area Under Curve Biological and medical sciences Calcium - agonists Calcium - blood chronic renal disease Double-Blind Method end-stage renal disease Endocrinopathies Female hemodialysis Humans Hyperparathyroidism, Secondary - blood Hyperparathyroidism, Secondary - drug therapy Hyperparathyroidism, Secondary - etiology Hypocalcemia - chemically induced Kidney Failure, Chronic - complications Male Medical sciences Middle Aged Nephrology. Urinary tract diseases Nephropathies. Renovascular diseases. Renal failure Non tumoral diseases. Target tissue resistance. Benign neoplasms parathyroid hormone Parathyroid Hormone - blood Parathyroids. Parafollicular cells. Cholecalciferol. Phosphocalcic homeostasis (diseases) Phenethylamines Propylamines R-568 Renal failure |
| title | A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T13%3A28%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20calcimimetic%20agent%20lowers%20plasma%20parathyroid%20hormone%20levels%20in%20patients%20with%20secondary%20hyperparathyroidism&rft.jtitle=Kidney%20international&rft.au=Goodman,%20William%20G.&rft.date=2000-07-01&rft.volume=58&rft.issue=1&rft.spage=436&rft.epage=445&rft.pages=436-445&rft.issn=0085-2538&rft.eissn=1523-1755&rft.coden=KDYIA5&rft_id=info:doi/10.1046/j.1523-1755.2000.00183.x&rft_dat=%3Cproquest_cross%3E980867351%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=210128746&rft_id=info:pmid/10886592&rft_els_id=S0085253815471169&rfr_iscdi=true |